Literature DB >> 9124077

Symptoms at index admission as predictor for 1-5 year outcome in schizophrenia.

I M Wieselgren1, E Lindström, L H Lindström.   

Abstract

A total of 107 drug-free schizophrenic patients (76 males and 31 females) were consecutively admitted to an emergency ward and rated for psychotic symptoms by means of 32 items from the Comprehensive Psychopathological Rating Scale (CPRS). They were followed prospectively with ratings of social functioning by use of Strauss-Carpenter's outcome scale at 1, 3 and 5 years after index admission with the aim of determining possible early symptoms that are predictors of social outcome. In total, 59 of the patients were first admissions and had never been treated. At index admission, no difference was found in total CPRS scores between first-admission patients and chronic readmitted patients, or between male and female subjects. When subscales for positive symptoms (flights of ideas, feeling controlled, disrupted thoughts, auditory hallucinations, ideas of persecution) and negative symptoms (indecision, withdrawal, reduced speech, lack of appropriate emotions, slowness of movements) from the CPRS were applied, no relationship between the two subscales and outcome scores was found. However, in patients with a duration of the disorder of less than 24 months before index admission, high scores on both negative and positive subscales were significantly correlated with a poor 5-year outcome. No correlation was found in the group with a duration of illness of more than 24 months before index admission. It is concluded that symptoms at index admission have a predictive value for outcome in schizophrenic patients. Negative symptoms measured by use of a subscale of the CPRS have a predictive value for outcome up to 5 years after index admission, but high scores on both positive and negative symptoms are more strongly associated with a poor outcome. The duration of the symptoms before admission, as well as the kind of neuroleptic treatment given (clozapine vs. classical neuroleptics), seem to be important factors for prediction of outcome. Our data support the view that early negative symptoms in particular have a predictive value for the prognosis in schizophrenia for up to 5 years.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9124077     DOI: 10.1111/j.1600-0447.1996.tb09866.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  9 in total

1.  Symptomatic remission in previously untreated patients with schizophrenia: 2-year results from the SOHO study.

Authors:  Diego Novick; Josep Maria Haro; David Suarez; Martin Lambert; Jean-Pierre Lépine; Dieter Naber
Journal:  Psychopharmacology (Berl)       Date:  2007-02-20       Impact factor: 4.530

2.  Histone methylation at H3K9: evidence for a restrictive epigenome in schizophrenia.

Authors:  Kayla A Chase; David P Gavin; Alessandro Guidotti; Rajiv P Sharma
Journal:  Schizophr Res       Date:  2013-06-28       Impact factor: 4.939

3.  Sex differences in schizophrenia and other psychotic disorders: a 20-year longitudinal study of psychosis and recovery.

Authors:  Linda S Grossman; Martin Harrow; Cherise Rosen; Robert Faull; Gregory P Strauss
Journal:  Compr Psychiatry       Date:  2008-06-03       Impact factor: 3.735

4.  Neuropsychological and cerebral morphometric aspects of negative symptoms in schizophrenia: negative symptomatology is associated with specific mnestic deficits in schizophrenic patients.

Authors:  Tobias Hornig; Gabi Valerius; Bernd Feige; Emanuel Bubl; Hans M Olbrich; Ludger Tebartz van Elst
Journal:  BMC Psychiatry       Date:  2014-11-25       Impact factor: 3.630

5.  The Mental Health Recovery Measure Can Be Used to Assess Aspects of Both Customer-Based and Service-Based Recovery in the Context of Severe Mental Illness.

Authors:  Albino J Oliveira-Maia; Carina Mendonça; Maria J Pessoa; Marta Camacho; Joaquim Gago
Journal:  Front Psychol       Date:  2016-11-03

6.  Sex differences in the course of schizophrenia across diverse regions of the world.

Authors:  Diego Novick; William Montgomery; Tamas Treuer; Maria Victoria Moneta; Josep Maria Haro
Journal:  Neuropsychiatr Dis Treat       Date:  2016-11-14       Impact factor: 2.570

7.  Relationships among neurocognition, symptoms and functioning in patients with schizophrenia: a path-analytic approach for associations at baseline and following 24 weeks of antipsychotic drug therapy.

Authors:  Ilya A Lipkovich; Walter Deberdt; John G Csernansky; Bernard Sabbe; Richard Se Keefe; Sara Kollack-Walker
Journal:  BMC Psychiatry       Date:  2009-07-14       Impact factor: 3.630

8.  Treatment outcome in patients receiving assertive community treatment.

Authors:  H E Kortrijk; C L Mulder; B J Roosenschoon; D Wiersma
Journal:  Community Ment Health J       Date:  2009-10-22

9.  Factors Influencing Rehospitalisation of Patients with Schizophrenia in Japan: A 1-year Longitudinal Study.

Authors:  Takeshi Shimada; Ai Nishi; Tomotaka Yoshida; Sachie Tanaka; Masayoshi Kobayashi
Journal:  Hong Kong J Occup Ther       Date:  2016-12-29       Impact factor: 0.917

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.